Skip to main content
Fig. 1 | BMC Pediatrics

Fig. 1

From: Study protocol: DexaDays-2, hydrocortisone for treatment of dexamethasone-induced neurobehavioral side effects in pediatric leukemia patients: a double-blind placebo controlled randomized intervention study with cross-over design

Fig. 1

Study Design DexaDays-2. Schematic study design of the DexaDagen-2 study. See Table 1 (Identification study) and Table 2 (RCT) for the specification of blood samples and questionnaires. RCT = randomized controlled trial. ALL = acute lymphoblastic leukemia. MR = medium risk. Dexa = dexamethasone

Back to article page

BMC Pediatrics

ISSN: 1471-2431

Contact us